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Abstract
Background: The lifetime prevalence of Social Phobia (SP) in European countries other than Italy
has been estimated to range from 3.5% to 16.0%. The aim of this study was to assess the frequency
of SP in Sardinia (Italy) in order to verify the evidence of a lower frequency of SP in Italy observed
in previous studies (from 1.0% to 3.1%).
Methods: A randomised cross sample of 1040 subjects, living in Cagliari, in rural areas, and in a
mining district in Sardinia were interviewed using a Simplified version of the Composite
International Diagnostic Interview (CIDIS). Diagnoses were made according to the 10th
International Classification of Diseases (ICD-10).
Results:  Lifetime prevalence of SP was 2.2% (males: 1.5%, females: 2.8%) whereas 6-month
prevalence resulted in 1.5% (males: 0.9%, females: 2.1%). Mean age at onset was 16.2 ± 9.3 years.
A statistically significant association was found with Depressive Episode, Dysthymia and
Generalized Anxiety Disorder.
Conclusions: The study is consistent with findings reported in several previous studies of a lower
prevalence of SP in Italy. Furthermore, the results confirm the fact that SP, due to its early onset,
might constitute an ideal target for early treatment aimed at preventing both the accumulation of
social disabilities and impairments caused by anxiety and avoidance behaviour, as well as the onset
of more serious, associated complications in later stages of the illness.
Background
Several epidemiological studies have attempted to
describe the prevalence, socio-demographic characteris-
tics, comorbidity, and severity of clinical manifestations
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of Social Phobia (SP). Quality of life and functional status
of affected individuals have also been investigated [1].
Lifetime prevalence of SP in European societies other than
Italy ranges from 3.5% to 16.0% [2]. As discussed in sev-
eral excellent review papers, these rate differences were
partly attributed to probable genetic or cultural factors [3].
Furthermore, major methodological differences (type of
diagnostic criteria used, assessment tools, age of the sam-
ple) affecting the estimates have been demonstrated [1].
This study, part of an extended epidemiological investiga-
tion "Health in Sardinia," aimed to assess the prevalence
rates of SP in Sardinia (Italy) in order to confirm the evi-
dence of low SP prevalence rates ranging from 1.0% to
3.1% observed in previous research projects in Italy [4-6].
The study also intended to evaluate the treatments and to
verify the comorbid psychiatric disorders in the identified
people with Social Phobia.
Methods
The sample, which had already been examined and
described in greater detail in a previously published study
[7], consisted of 1040 subjects recruited throughout the
island of Sardinia, Italy. 393 subjects came from the city
of Cagliari, 344 from rural areas, and 303 from an indus-
trial mining district, thus representing fairly well all socio-
economic strata present on the island. The age distribu-
tion of the sample is shown in table 1, with age range from
18 to 89 years. 79.2% out of a total of 1313 subjects
approached, agreed to take part in the study, 12.5%
refused to participate, and 8.3% could not be traced; the
final sample did not differ respect to the population of
origin with reference to the variables applied in stratifica-
tion (Table 1). All subjects were interviewed "face to face"
by trained physicians using a Simplified version of Com-
posite International Diagnostic Interview (CIDI) [8],
hence the acronym CIDI "Simplified" (CIDIS) [9,10]. The
version used in this study had been translated into Italian
and back-translated into the original French language
under blind conditions respect to the first translation, by
a bilingual researcher; approval of the final version was
obtained from the original authors [11]. The CIDI struc-
tured interview in its various versions currently represents
the most widely used diagnostic tool in psychiatric epide-
miological studies conducted on the general population
[12]. The CIDIS is a highly structured tool made up of 5
sections which investigate respectively: Somatoform Dis-
orders and General Medical Conditions, Anxiety Disor-
ders, Depressive Disorders, Substance-Related Disorders
(Alcohol-Related Disorders and Substance-Related Disor-
ders) and Eating Disorders. The computer elaboration of
data obtained through application of the CIDIS enables
calculation of both "lifetime prevalence" and, for the pre-
ceding six months, a series of psychiatric disorders (those
more frequently observed in the general population)
according to the ICD-10 diagnostic system [13]. This
interview moreover enhances identification of both the
type of therapist referred to and treatment already used by
each patient for his or her specific problem and definition
of degree of impact of the problem on the subject's daily
routine. An ad hoc computer algorithm ascertained the
presence of the disorders according to ICD-10 criteria
[13], both in the past six months and in the lifetime. The
items of the CIDIS concerning Social Phobia and the
related algorithm is reported in Figure 1.
Results
Estimates of lifetime SP prevalence of 2.2% were found
(males: 1.5%, females: 2.8%), with no statistically signifi-
cant difference between the sexes (χ2 = 1.2, 1DF, P = 0.25).
6-month prevalence rates were lower (total: 1.5%, males:
0.9%; females: 1%; no significant difference between the
sexes, χ2 = 1.6, 1DF, P = 0.13). Table 2 compares results
obtained in this study with those of the major research
projects carried out in Europe and the USA [4,5,14-23].
Table 3 illustrates the lifetime prevalence according to age
and sex, and Table 4 shows the 6-month prevalence
according to age and sex. An increased frequency of SP
among the younger age groups was observed, although
distribution in males resulted as being less homogeneous.
In no case statistical significance was reached. Lifetime
prevalence rates of SP respect to marital status of subjects
studied were as follows: 3.0% among the unmarried;
1.2% among married subjects; and 3.5% among the
divorced, separated and widowed (χ2 = 5.8, 1DF, P =
0.06). Mean age at onset was 16.2 ± 9.3 years.
During the week prior to the study, 8 (50.0%) out of the
16 subjects who had been diagnosed with SP over the past
six months had been taking low doses of anxiolytics (less
than the equivalent of 2 mg of Lorazepam). 3 (18.7%)
were on antidepressants, one of whom (6.2%) at non-
therapeutic doses, and 1 subject (6.2%) was undergoing
Table 1: Percentage of subdivision according to age, sex, and 




AGE 18–24 146 (14.0%)
AGE 25–44 353 (33.9%)
AGE 45–64 310 (29.8%)
AGE >64 231 (22.2%)
UNMARRIED 370 (35.6%)
MARRIED 571 (54.9%)
WIDOWED/SEPARATED/DIVORCED 99 (9.5%)BMC Psychiatry 2004, 4:31 http://www.biomedcentral.com/1471-244X/4/31
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The Composite International Diagnostic Interview Simplified (CIDIS) [9, 10] algorithm for the diagnosis of Social Phobia Figure 1
The Composite International Diagnostic Interview Simplified (CIDIS) [9, 10] algorithm for the diagnosis of Social Phobia.
19) Some individuals experience a phobia, a marked  and unreasonable fear when in the presence of 
specific objects or situations. Those objects or situations are usually avoided even though they do 
not represent any real danger. Did you ever have an excessive fear of an object or a situation that   
leaded you to avoid the object or the situation?
19b) Did you ever have a marked and unreasonable fear in the presence of  others, fear of speaking or 
eating in public or in groups, that leaded you to avoid those social or performance situations in which
embarrassment may occur?
20) Did you feel markedly 
distressed when you thought 
or when you were exposed to 
those situations? 
23)Did the fear lead 
you to avoid going 
outside or impair your 
ability to travel, work 
or carry out your 
responsibilities?
21) Did you ever avoid 
those situations  because 
you had a marked and 
unreasonable fear?
22) Did the fear of encountering those 
situations interfere significantly with 
your daily routine, occupational or 
academic functioning, or social 
activities or relationships?
24a) Did you ever talk with a 
physician or another health 
professional about your 
marked fear?
24b) Did you ever take drugs 
for your excessive fear for at 
least 2 times?
24c) Did the fear damage 
your life, your work or 
your daily activities?   
25) When did you have the marked fear for the first time? 
-Recently or during the last month?  
-From 1 to 6 months ago? 
-More than 6 month ago? How old were you? 
26) When did you have the marked fear for the last time? 
-Recently or during the last month?  
-From 1 to 6 months ago? 













Period PrevalenceBMC Psychiatry 2004, 4:31 http://www.biomedcentral.com/1471-244X/4/31
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cognitive behavioural psychotherapy. The remaining 6
subjects (37.5%) were not on any treatment.
Six out of the 10 treated subjects (60%) were being super-
vised by their general practitioners (GP), 1 (10%) by a
neurologist and 2 (20%) by psychiatrists. All subjects pre-
sented some degree of comorbidity with Depressive Epi-
sodes (DE), Panic Attack Disorder (PAD), and
agoraphobia (AP). Only 1 subject (10%) was undergoing
cognitive behavioural therapy with a psychologist/psy-
chotherapist.
Table 5 illustrates the rate of comorbidity with major psy-
chiatric disorders observed in the general population, as
well as the degree (OR) of associated disorders observed
with regard to frequency reported for the latter in popula-
tions not affected by SP. A statistically significant differ-
ence was revealed for association with DE, Dysthymia
(DD), and Generalized Anxiety Disorder (GAD). In spite
of their increased frequency among patients affected by
SP, disorders such as PAD and Specific Phobia do not rep-
resent a statistically significant association. The mean age
at onset of comorbid DE was 6.5 ± 6.6 years subsequent
to onset of SP, whereas GAD was manifested at a mean of
4.3 ± 7.8 years later.
Discussion
Several epidemiological studies carried out in Europe
(Switzerland [16,21], France [19,22], Germany [23]) and
in the USA [15,17], recently reviewed by Furmark [2], sug-
gest that SP is one of the more frequently observed anxiety
disorders in the general population in Western countries.
However, frequency rates reported in the various studies
differ from country to country and according to time and
evaluation methods used. Indeed, the two American stud-
ies [15,17] carried out at an interval of approximately 15
years, illustrate distinctly contrasting results, and it is hard
to establish what factors really determine variance in
findings.
The present study is consistent with the tendency towards
rather low lifetime prevalence rates of SP observed in
Table 2: Lifetime prevalence of Social Phobia in the general population of Europe and USA.
Country Reference Diagnostic criteria N Male Female Total
Italy Faravelli et al., 1989 [4] DSM-III-R 1110 1.0
Switzerland Wacker et al., 1992 [16] DSM-III-R 470 16.0
ICD-10 9.6
ECA (USA) Schneier et al., 1992 [15] DIS 18571 2.0 3.1 2.4
Iceland Lindal and Stefansson, 1993 [32] DSM-III 862 2.5 4.5 3.5
Switzerland Degonda and Angst, 1993 [21] DSM-III 591 3.1 5.7 4.4
NCS (USA) Kessler et al., 1994 [17] CIDI 8098 11.1 15.5 13.3
France Lepine and Lellouch, 1995 [19] 2.1 5.4 4.1
Germany Wittchen et al., 1998 [23] DSM-IV 3021 2.2 4.8 3.5
Italy Carta and Rudas, 1998 [6] CIDI 783 1.7 4.6 3.1
Spain Arillo et al., 1998 [cited in 33] DIS 237 8.9
Netherlands Bijl et al., 1998 [20] DSM-III-R 7076 5.9 9.7 7.8
France Lépine and Pélissolo, 1999 [22] DSM-IV 7.3
Italy Faravelli et al., 2000 [5] FPI/CIDI 2355 1.9 4.0 3.1
Italy Carta et al., 2002 [7] CIDI 1040 1.5 2.8 2.2
Table 3: Lifetime prevalence N (%) of Social Phobia according to 
age and sex.
Age Male OR Female OR Total OR
<25 1 (1.3) 0.9 4 (5.0) 2.3 5 (3.4) 1.7
25–44 4 (2.5) 2.5 4 (2.1) 0.7 8 (2.2) 1.1
45–64 1 (0.7) 0.4 4 (2.4) 0.8 5 (1.6) 0.6
>65 1 (1.1) 0.7 4 (2.8) 1.1 5 (2.2) 0.9
Male according to age χ2 with Yathes correction = 1.6, 3 df, p = 0.89; 
female according to age χ2 with Yathes correction = 2.2, 3 df, p < 
0.71; total sample according to age χ2 with Yathes correction = 1.8, 3 
df, p = 0.82
Table 4: Six month prevalence N (%) of Social Phobia according 
to age and sex.
Age Male OR Female OR Total OR
<25 1 (1.5) 1.8 3 (3.7) 2.0 4 (2.7) 2.1
25–44 1 (0.6) 0.6 3 (0.7) 0.5 4 (1.1) 0.6
45–64 1 (0.7) 0.7 2 (1.1) 0.5 3 (0.9) 0.5
>65 1 (1.1) 1.4 4 (2.8) 1.4 5 (2.1) 1.6
Male according to age χ2 = 0.6, 3 df, p = 0.98; female according to age 
χ2 with Yathes correction = 3.4, 3 df, p = 0.44; total sample according 
to age χ2 with Yathes correction = 3.4, 3 df, p = 0.44BMC Psychiatry 2004, 4:31 http://www.biomedcentral.com/1471-244X/4/31
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other Italian research projects. If we take into account only
those European researches that adopted ICD-10
diagnosis, our results seem to indicate a lower frequency
than a study carried out in Formentera, Spain (lifetime
prevalence of 2.8% against 8.9% in females [cited in
[33]]) and Basel, Switzerland (lifetime prevalence in the
total sample 2.2 against 9.6% [16]). However, lower fre-
quencies emerged also in Italian surveys conducted using
different methods [5,7]. The Italian studies were carried
out over a considerable period of time and in two distinct
areas: the Florence area [4,5] and Sardinia [[6], the present
study]. It is therefore quite likely that the lower frequen-
cies observed may be the result of an effectively reduced
vulnerability of Italians to SP. The results of this study can
indeed be assumed as being influenced by several cultural
variables – the genetic diversity of the two populations
examined, as well as the considerable genetic variance of
the Sardinian population respect to other European pop-
ulations [24,25].
Findings for six-month prevalence show lower frequen-
cies than those evidenced in the recent studies: 1.5%
against 4.0% in Iceland [26] and against 4.0% in Munich
[14]. Our rates are lower than E.C.A. findings: 2.7% in
Duke [27] and 2.2% in Baltimore, New Haven, and Saint
Louis [28]. The 6-month prevalence rates obtained in
Sardinia are similar only to data reported for Edmonton
(1.2%) from a survey carried out more than 15 years ago
[29] and published in 1994 [30]. However, the prevalence
data emerging from this study further justify the consider-
able interest shown in this disorder from both a medical
and a social point of view. This research confirms the fact
that onset of the illness occurs primarily during childhood
and adolescence [31], thus underlining the suitability of
the condition as a candidate for early treatment aimed at
preventing both the slow accumulation of social disabili-
ties and impairment caused by anxiety and by avoidance
behaviour, as well as the onset of more serious complica-
tions (e.g., DE or GAD), which may be manifested many
years after onset of SP. Indeed, subjects affected by social
phobia presented a high risk of comorbidity with both the
latter disorders and DD [1] .
It should be underlined that 60% of subjects undergoing
treatment (not all affected subjects) chose their general
practitioner (GP). This view is corroborated by the fact
that those patients treated by a psychiatrist invariably pre-
sented comorbidity with DE, PAD, and AP, thereby repre-
senting the more severely affected from a
psychopathological point of view. Overall however, the
low rate of patients with SP treated with first line-treat-
ments is alarmingly low.
In the future, serious attempts should be made to improve
the GPs' abilities to recognise SP in order to prevent the
use of inappropriate treatments, such as insufficient doses
of benzodiazepines, which may be linked to the physi-
cian's incorrect diagnosing of the disorder. Due to the fact
that subjects affected by SP most frequently refer to their
GP, the importance of preventing SP as opposed to other
types of disorders, as well as the markedly incapacitating
nature of SP reinforce this necessity for a better training of
GPs.
It is however mandatory to briefly acknowledge some
potential limitations of this study. First, the number of
cases and the sample size is too small to allow firm con-
clusions to be drawn concerning the true rate and the
degree to which they might actually differ from previous
studies with higher estimates. Secondly, differences in the
assessment strategy might have resulted in a diminished
comparability.
Conclusions
The study is consistent with findings reported in several
previous studies of a lower prevalence of Social Phobia in
Italy and confirms the fact that onset of the illness occurs
primarily during childhood and adolescence. Further-
more, the results confirm the fact that SP, due to its early
onset, might constitute an ideal target for early treatment
aimed at preventing both the accumulation of social disa-
bilities and impairments caused by anxiety and avoidance
behaviour, as well as the onset of more serious, associated
complications in later stages of the illness, or many years
after onset of SP.
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Table 5: Lifetime comorbidity of Social Phobia.
N (%) OR χ2
Depressive Episode (DE) 9 (39.1) 4.3 11.1*
Dysthymia (DD) 5 (21.7) 7.1 14.1*
Generalized Anxiety Disorder (GAD) 10 (43.4) 6.5 20.9*
Panic Attack Disorder (PAD) 2 (8.7) 3.3 1.1
Specific Phobia 1 (4.3) 8.6 1.6
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